Scholars Central

Conference abstractPublished 15 Jul 2013

Observational comparative study on the effect of intravenous omega 3 fatty acids (Omegaven) on quality of life and nutritional status of patients with advanced cancer

Authors: Jamal Zidan, Sigalit Tamam, Yhudit Sher, Amira Abzah, Shlomit Yohay

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Purpose: The importance of nutrition support in cancer patients is in consensus. Cancer cachexia is a syndrome characterized by progressive involuntary weight loss. Clinical features include host tissue wasting, anorexia, skeletal muscle atrophy, fatigue, anemia, and hypoalbuminemia. Calories rich diets are not enough to help cancer cachexia patients to raise a weight and to improve their quality of life. Several studies found omega 3 fatty acids helpful in stabilizing weight or decrease the rate of weight loss in advanced cancer patients. The aim of this study is to evaluate the efficacy of intravenous (IV) omega 3 fatty acids (omegaven. Fresenius Kabi) on quality of life and weight of patients with advanced and metastatic malignancies. Methods: Fifty patients with advanced cancer were given omegaven IV once every one week. Omegaven includes 10 gr highly refined fish oil, 1.25-2.82 gr eicosapentaenoic acid, 1.44-3 gr docosahexaenoic acid and other acids in 100 ml emulsion given by IV infusion. Total energy in one infusion is 470 kJ/100 ml=112 kcal/100ml. Some patients received only omegaven and others received omegaven and chemotherapy sequentially. Characteristics of patients with omegaven were compared with their characteristics before administration of omegaven and with a control group not receiving omigaven. Results: Average duration of treatment was 11 weeks (range: 3-24 weeks). 15 patients in control group who did not receive omegaven had 4.1 kg weight loss during this period. Patients in the omegaven group had lost 4.19 kg of their weight before omegaven, while they had increased weight by an average of 2.24 kg after omegaven (p=0.02). Performance status had increased from 50% before omegaven to 60% after omegaven. Total protein levels increased by 0.34 mg in average after omegaven and albumin by 0.24 mg compared to baseline levels before omegaven (p=0.04). 80% of patients reported on improvement of their quality of life after 4-4 weeks of omegaven. No side effects were documented. Summary: Intravenous omigaven increased significantly weight, performance status, proteins and quality of life in advanced cancer patients. No side effects were reported. Omegaven given IV given seems safe and effective in cancer cachexia patients.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Nutrition & Food Sciences.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Nutrition & Food Sciences
  • SubjectNutrition & Food Science
  • BylineArticles whose byline prints “Jamal Zidan”
  • BylineArticles whose byline prints “Sigalit Tamam”
  • BylineArticles whose byline prints “Yhudit Sher”
  • BylineArticles whose byline prints “Amira Abzah”
  • BylineArticles whose byline prints “Shlomit Yohay”